AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...

AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for trea ...

AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...

(IN BRIEF) AstraZeneca and Daiichi Sankyo announced that their drug Enhertu (trastuzumab deruxtecan) has been granted Priority Review by the US FDA for treating patients with unresectable or ...

On Friday, Bernstein SocGen Group maintained its Outperform rating on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY), with a steady price target of JPY6,400.00. The firm's outlook remains ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application ...

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Tuesday said their cancer drug Enhertu received a priority review by the Food & Drug Administration in the US for some forms of breast ...

For EU media only Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced final 2-year follow-up data from the German cohort of the multinational, European observational MILOS study.1 The ...

On Friday, Bernstein SocGen Group maintained its Outperform rating on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY), with a steady price target of JPY6,400.00. The firm's outlook remains ...

On Tuesday, Jefferies maintained a Buy rating on Daiichi Sankyo Company, Limited (4568:JP) (OTC: DSNKY) with a JPY6,600.00 price target. The endorsement follows Daiichi Sankyo's ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.